Latest Nouscom News & Updates

See the latest news and media coverage for Nouscom. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Nouscom

Cancer immunotherapy biotechnology company

nouscom.com
Headquarters
BS, Switzerland
Company type
Private company
Number of employees
50–59

Last updated

Latest news about Nouscom

In short: Nouscom raised €120 million to advance NOUS-209 into a global pivotal Lynch syndrome trial.

Company announcements

Nouscom

Nouscom reports positive Phase 2 results for NOUS-209

The immunotherapy combined with pembrolizumab achieved a 15% objective response rate and 70% disease control rate in patients refractory to anti-PD-1 therapy.

Unlock all announcements with a

Media coverage

Yahoo Finance

Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy ...

While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients either don't...

Unlock all articles with a

Never miss news about Nouscom

Track Nouscom and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.